Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 4/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27591629 | 1.00 | RELA (0.48) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL27591426 | 1.00 | RELA (0.48) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL7093133 | 0.97 | GNAI3 (0.48) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL7497784 | 0.97 | GNAI3 (0.48) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL7095309 | 0.97 | GNAI3 (0.48) | RELAGNAI3GNAO1GNAI1ANPEP | |
| Hydrochloric Acid SCHEMBL7096803 | 0.95 | GNAI3 (0.47) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL6825299 | 0.95 | GNAI3 (0.49) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL10382687 | 0.95 | SPHK1 (0.44) | RELAGNAI3GNAO1GNAI1ANPEP | |
| SCHEMBL9705885 | 0.93 | GNAI3 (0.50) | GNAI3GNAO1GNAI1ANPEPERAP2 | |
| Oxalic Acid SCHEMBL27591695 | 0.93 | RELA (0.46) | RELAGNAI3GNAO1GNAI1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | WOODLE MARTIN C (US) | 2003-09-04 | — | — | US | disclosed |
| EP-1242609-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | Novartis AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049324-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | NOVARTIS AG (CH) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | FUS, HNRNPUL2, HNRNPH1 | RELA 2728/4885GNAI3 2162/4885GNAO1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.